Mubadala Investment Co PJSC purchased a new stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 16,805 shares of the medical instruments supplier's stock, valued at approximately $3,813,000. Becton, Dickinson and Company comprises about 0.0% of Mubadala Investment Co PJSC's portfolio, making the stock its 24th largest position.
Other large investors have also recently modified their holdings of the company. Bank of Jackson Hole Trust bought a new position in shares of Becton, Dickinson and Company during the fourth quarter valued at $25,000. Sierra Ocean LLC bought a new position in shares of Becton, Dickinson and Company during the fourth quarter valued at $29,000. Picton Mahoney Asset Management raised its stake in shares of Becton, Dickinson and Company by 61.4% during the fourth quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock valued at $32,000 after acquiring an additional 54 shares during the last quarter. Hopwood Financial Services Inc. bought a new position in shares of Becton, Dickinson and Company during the fourth quarter valued at $39,000. Finally, CoreFirst Bank & Trust bought a new position in shares of Becton, Dickinson and Company during the fourth quarter valued at $50,000. Institutional investors own 86.97% of the company's stock.
Wall Street Analyst Weigh In
Several equities analysts have recently issued reports on the stock. Stifel Nicolaus dropped their price target on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Wells Fargo & Company downgraded shares of Becton, Dickinson and Company from an "overweight" rating to an "equal weight" rating in a research note on Thursday, May 1st. Bank of America downgraded shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 target price for the company. in a research note on Thursday, May 1st. StockNews.com downgraded shares of Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a research note on Friday, May 2nd. Finally, Piper Sandler downgraded shares of Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and lowered their target price for the stock from $260.00 to $185.00 in a research note on Friday, May 2nd. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $231.44.
View Our Latest Research Report on Becton, Dickinson and Company
Insider Activity
In other news, EVP Michael David Garrison sold 479 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total transaction of $94,497.12. Following the completion of the transaction, the executive vice president now directly owns 4,887 shares in the company, valued at $964,107.36. This trade represents a 8.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Richard Byrd sold 459 shares of Becton, Dickinson and Company stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $230.00, for a total transaction of $105,570.00. Following the transaction, the executive vice president now owns 6,952 shares of the company's stock, valued at $1,598,960. This represents a 6.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 2,878 shares of company stock worth $636,393 over the last three months. 0.36% of the stock is currently owned by insiders.
Becton, Dickinson and Company Stock Up 1.8%
BDX traded up $3.10 during midday trading on Friday, hitting $175.37. The company had a trading volume of 2,253,035 shares, compared to its average volume of 1,907,136. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99. The company has a quick ratio of 0.63, a current ratio of 1.13 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $50.26 billion, a price-to-earnings ratio of 29.13, a PEG ratio of 1.63 and a beta of 0.31. The stock's 50 day moving average price is $203.61 and its 200 day moving average price is $220.91.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, beating the consensus estimate of $3.28 by $0.07. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. The firm had revenue of $5.27 billion during the quarter, compared to the consensus estimate of $5.35 billion. During the same period in the previous year, the firm posted $3.17 earnings per share. The business's revenue was up 4.5% compared to the same quarter last year. On average, research analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.
Becton, Dickinson and Company Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Monday, June 30th. Shareholders of record on Monday, June 9th will be paid a $1.04 dividend. This represents a $4.16 annualized dividend and a yield of 2.37%. The ex-dividend date of this dividend is Monday, June 9th. Becton, Dickinson and Company's dividend payout ratio (DPR) is currently 79.39%.
Becton, Dickinson and Company declared that its Board of Directors has initiated a share repurchase plan on Tuesday, January 28th that allows the company to buyback 10,000,000 shares. This buyback authorization allows the medical instruments supplier to repurchase shares of its stock through open market purchases. Stock buyback plans are usually a sign that the company's board of directors believes its shares are undervalued.
Becton, Dickinson and Company Company Profile
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Featured Stories
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
